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Abstract
Background:  Inflammatory processes are considered to participate in the development of
cardiovascular disease (CVD). Statins have been used successfully in the prevention and treatment
of coronary heart disease. Chronic periodontitis has been suggested to contribute to CVD. The
aim of this study was to examine the association of statin use and clinical markers of chronic
periodontitis.
Methods: Periodontal probing pocket depth (PPD) values were collected from dental records of
100 consecutive adult patients referred to a university dental clinic for treatment of advanced
chronic periodontitis. A novel index, Periodontal Inflammatory Burden Index (PIBI), was derived
from the PPD values to estimate systemic effects of periodontitis.
Results: Periodontitis patients taking statins had a 37% lower number of pathological periodontal
pockets than those without statin medication (P = 0.00043). PIBI, which combines and unifies the
data on PPD, was 40% smaller in statin using patients than in patients without statin (P = 0.00069).
PIBI of subjects on simvastatin and atorvastatin both differed significantly from patients without
statin and were on the same level. The subjects' number of teeth had no effect on the results
Conclusion: Patients on statin medication exhibit fewer signs of periodontal inflammatory injury
than subjects without the statin regimen. PIBI provides a tool for monitoring inflammatory load of
chronic periodontitis. The apparent beneficial effects of statins may in part be mediated by their
pleiotropic anti-inflammatory effect on periodontal tissue.
Background
Statins are inhibitors of hydroxymethylglutaryl coenzyme
A (HMG-CoA) reductase. They were developed for the
reduction of serum cholesterol levels [1], and have been
used successfully in the prevention and treatment of coro-
nary heart disease. [2-4]. Recently, interest has focused on
non-cholesterol-dependent, pleiotropic effects of statins
[5-7]. Anti-inflammatory pleiotropic effects are supposed
to result from the inhibition of isoprene modification of
signal transducers of inflammation [7].
Inflammatory processes are considered to participate in
the development of cardiovascular disease (CVD) [8-11].
In addition to local inflammatory reactions in the arterial
wall, chronic inflammatory processes in other tissues have
been suggested to impose a systemic burden on the arter-
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ies, thus contributing to CVD. This systemic inflammation
involves an increase in serum C-reactive protein, recently
identified as a risk marker of atherosclerosis [12].
Gingivitis is one of the most prevalent localized inflam-
matory diseases in the adult population [13,14]. If left
untreated, it may proceed to chronic periodontitis, a con-
tinuous inflammatory process resulting in irreversible per-
iodontal tissue destruction [15]. This medium-grade
inflammation may place a considerable burden on the
cardiovascular system and contribute to CVD [15-18], and
has been shown to be associated with systemic inflamma-
tion [19]. In this retrospective study, our aim was to exam-
ine the association of statin use and clinical indices of
chronic periodontitis.
Methods
The study protocol was approved by the Helsinki Health
Centre Research Coordination Committee. Because the
investigation involved only the review of patient records
obtained during the course of medical care, no patient
consent was required.
Data were collected from the dental records of 100 con-
secutive patients aged 40 years or older, who had been
referred to the University Dental Clinic, Health Centre of
Helsinki, for treatment of advanced chronic periodontitis
during 2004–2005. Each patient was assigned an
encrypted code linking the research data to the patient
documents. Subjects with more than 14 teeth were
included in the analysis. Patients using statins were com-
pared with those who did not use statins.
We extracted the following data from the patient records:
age, gender, reported current smoking, and use of statin
medication. In addition, the records were checked for
other medications, diabetes, rheumatoid diseases, and
indicators of periodontal health.
A visible plaque index for index teeth [20] was extracted
from the records.
For all teeth, we extracted recordings of six periodontal
Probing Pocket Depth (PPD) values, measured to the
nearest millimetre, from mesiobuccal, midbuccal, disto-
buccal, distolingual, midlingual, and mesiolingual sur-
faces using a WHO periodontal probe. [21-24]. Data on
bleeding on probing was recorded for index teeth only
and not included in the study. For a full dentition of 28
teeth, this yields 168 measurements. A gingival sulcus is
considered physiological when PPD is less than 4 mm.
The number of sites with moderate periodontal lesions
(PPD at least 4 mm and less than 6 mm, modPPD) and
advanced periodontal lesions (PPD 6 mm or deeper,
advPPD) were recorded separately. For a dentition of 28
teeth, both of these indicators yield a maximum value of
6 × 28 = 168.
A novel index, Periodontal Inflammatory Burden Index or
PIBI, was derived from the PPD values. The index is calcu-
lated by adding the number of periodontal sites indicating
moderate periodontitis (NmodPPD) to the weighted
number of periodontal sites indicating advanced perio-
dontitis (NadvPPD).
NmodPPD = number of sites with moderate periodontal 
lesions (1)
NadvPPD = number of sites with advanced periodontal 
lesions (2)
PIBI = ∑ (NmodPPD + 2 NadvPPD)( 3 )
If all measurement sites are advPPD in a 28-tooth denti-
tion, PIBI can reach a maximum value of 336.
Statistical analysis
Student's t-test was used to compare the means of the out-
come variables following normal distribution. Kol-
mogorov-Smirnov test was used to estimate normality of
the distribution, and Levene's test the equality of vari-
ances. The distribution-free Mann-Whitney U-test was
applied to compare the medians when the values were not
normally distributed [25]. The results are given as mean,
standard error (SE), and the number of subjects in the
group, unless otherwise indicated. The 95% confidence
intervals and exact two-tailed p-values are given for each
comparison.
In order to examine relationships between subjects' back-
ground variables and the number of periodontal pockets
and PIBI, linear regression analysis was performed sepa-
rately for the statin using patients and patients without
statin.
Statistical calculations were performed using SPSS version
13.0 software (SPSS Inc., Chicago, Illinois) when appro-
priate.
Results
Patient characteristics
The demographic data of study subjects are presented in
Table 1. Of the 100 consecutive patients referred to the
clinic for periodontal treatment, three did not fulfil the
inclusion criteria of having at least 50% of the dentition
remaining. Of the eligible subjects (n = 97), 44 were
women. The mean age of all study subjects was 53 years
(range 42–69 years, Table 1).BMC Oral Health 2008, 8:16 http://www.biomedcentral.com/1472-6831/8/16
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The percentage of smokers was greater in statin users
(28.6%) than in patients not receiving statin (18.4%).
Diabetes was more frequent in statin users (28.6% vs.
3.9%). The percentage of patients with rheumatic disease
was similar in both groups.
The number of remaining teeth of statin-using patients
was 24.3 (SE 0.7) when that of non-using patients was
26.1 (SE 0.4). All subjects had poor oral hygiene, evident
as visible dental plaque and gingival bleeding on probing.
Twenty-one subjects were on statin medication: 11 used
atorvastatin, 7 simvastatin, 2 fluvastatin, and 1 rosuvasta-
tin. All statin-using patients were receiving a conventional
low-dose statin therapy.
Periodontal inflammatory injury
Numbers of periodontal pockets in subjects with and
without statin medication are shown in Figure 1 (means/
medians and 95% CIs). In patients not using statins, the
number of at least 4 mm deep periodontal pockets was
79.1 (SE 3.7; n = 76) (Figure 1A). In patients using statins,
the corresponding number was 50.1 (SE 7.0; n = 21),
being 37% lower than non-users. The difference of means
was 29.0 (95% CI 12.9–45.0; P = 0.00043) (Table 2).
Data were analysed separately for the number of moderate
periodontal lesions and advanced periodontal lesions. In
patients without statins, NmodPPD indicating moderate per-
iodontal lesions was 50.7 (SE 2.5; n = 76). In statin users,
NmodPPD was 36.0 (SE 5.0; n = 21), being 29% lower than
in the non-using patients. The difference of means was
14.7 (95% CI 3.2–26.2; P = 0.0087) (Table 2).
Advanced periodontal inflammatory injury was measured
as the number of periodontal pockets at least 6 mm deep.
For patients without statin, NadvPPD was 28.4 (SE 2.6; n =
76). The corresponding number for statin using patients
was 14.2 (SE 3.8; n = 21), being 50% lower than in
patients not using statins. The difference of means was
14.2 (95% CI 4.9–23.5; P = 0.0034). The NadvPPD data
indicating advanced periodontal lesions did not follow
normal distribution. We therefore also used the distribu-
tion-free Mann-Whitney U-test to compare the popula-
tion medians. The median was 20 for non-users and 11
for statin users. By the method of Campbell and Gardner
[25], the estimated difference in population medians was
11 and the approximate 95% CI for the difference in pop-
ulation medians 4–20 (P = 0.0010) (Figure 1B, Table 2).
The Periodontal Inflammatory Burden Index (PIBI) com-
bines and unifies data on PPD. In patients not taking stat-
ins PIBI was 107.6 (SE 5.8; n = 76) and in statin-using
patients 64.3 (SE 10.0; n = 21) (Figure 1C). The difference
of the means was 43.1 (95% CI 19.5–66.7; P = 0.00069).
In statin users, PIBI was 40% smaller than in other perio-
dontitis patients. For the non-smoking patients, PIBI was
64% lower for statin users when compared to patients
without statin (48.9 vs. 105.2).
The comparison of PIBI in subjects using simvastatin and
atorvastatin is presented in Figure 2. Subjects on simvasta-
tin as well as those on atorvastatin showed 40% lower
mean PIBI values than subjects without statin. We
observed no difference in PIBI between subjects on simv-
astatin or atorvastatin. The small number of subjects on
fluvastatin or rosuvastatin did not allow their inclusion in
the comparison.
To describe average periodontal injury, we divided the
PPD values and PIBI by the number of teeth. The tooth-
adjusted means of all of these clinical periodontal inflam-
matory signs were consistently lower in statin-users than
in non-users (Table 2).
Linear regression analysis of the effect of background var-
iables on the outcome variables revealed that smoking
and diabetes were associated with a higher number of per-
iodontal pockets among statin using patients, but not in
those without statin (Table 3). The subject's age did not
have an effect on the observed differences in the number
of periodontal pockets between statin users and non-
users. Age had no effect on PIBI in statin users, but
explained 5% of the variation in PIBI of subjects not hav-
ing a statin medication (Table 3).
Discussion
Strengths and limitations of the study
The primary data of this cross sectional, retrospective
study based on clinical records of periodontitis patients
can be considered reliable due to the extensive clinical
examination protocol used for educational purposes in
Finnish dental schools. The accuracy of the entries and the
thoroughness of clinical examinations are controlled by
senior staff members. The retrospective nature of the study
places limits to external calibration of the measurements,
Table 1: Description of study participants (n = 97)
Statin users Non-users
n%n%
Patients 21 76
M e n 1 36 1 . 94 05 2 . 6
Women 8 38.1 36 47.4
Smokers 6 28.6 14 18.4
Diabetes 6 28.6 3 3.9
Rheumatic disease 1 4.8 5 6.6
Years Range Years Range
Mean age (SD) 57.4 (8.7) 44–69 52.3 (8.5) 42–69BMC Oral Health 2008, 8:16 http://www.biomedcentral.com/1472-6831/8/16
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Scatter plots of the number of periodontal pockets and periodontal inflammatory burden index in subjects with and in subjects  without statin medication Figure 1
Scatter plots of the number of periodontal pockets and periodontal inflammatory burden index in subjects with and in subjects 
without statin medication. A. Number of periodontal pockets at least 4 mm deep. B. Number of periodontal pockets at least 6 
mm deep. C. Periodontal inflammatory burden index. Long bars represent means in A and C, and medians in B. Short bars 
represent upper and lower 95% confidence limits.
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and limits the interpretation of our measurements to the
realm of a university dental clinic and the results are not
necessarily applicable to a local dentist's practice.
Our subjects are Finnish adults from Helsinki area with
advanced chronic periodontitis, either receiving regular
statin medication or without statin medication. The
number of teeth [26] as well as the percentage of statin
users [27] in our subjects coincides well with that reported
for this age group in Finland.
Clinical signs of periodontal tissue destruction have been
reported to increase with age [28]. In our study this effect
of age was evident for subjects not using statins. Interest-
ingly, however, the effect of age could not be detected in
statin users.
Diabetes is frequent among CVD patients [29]. This
explains the higher percentage of diabetics in our statin-
using patients when compared to non-users. Also, the
proportion of current smokers was higher in statin-using
than in non-using patients of this study. Both diabetes
and smoking are predisposing factors for deterioration of
periodontal tissue [15]. In spite of this, the positive effect
on periodontal health observed in the statin using group
was clear and statistically significant.
Low socio-economic status has been reported as a predis-
posing factor for chronic periodontitis [30]. CVD is asso-
ciated with low socio-economic status [31]. Statin users
are CVD risk patients. Thus, it is unlikely that statin med-
ication selects patients with high socio-economic status
and that this could affect the results.
The inflammatory potential of dentition is proportional
to the number of teeth. All of our subjects had at least 15
remaining teeth, thus having at least 50% of the total pos-
sible dental inflammation sites. The small difference in
the number of teeth between the groups did not affect the
results. Statins had a substantial positive effect on local
Statin subgroups and periodontal inflammatory injury Figure 2
Statin subgroups and periodontal inflammatory injury. Com-
parison of periodontal inflammatory burden index. The col-
umns represent non-using patients (set to 100%), simvastatin 
users and atorvastatin users. The whiskers represent 95% 
confidence intervals for the means.
Table 2: Statin medication and periodontal inflammatory injury.
Non-users n = 76 Statin users n = 21 Difference (% of control) 95% CI (difference of means) P-value*
A. Inflammatory burden†
PPD‡ ≥ 4 mm 79.1(3.7) 50.1 (7.0) 29.0 (-37%) 12.9 – 45.0 0.00043
4 mm ≤ PPD < 6 mm 50.7 (2.5) 36.0 (5.0) 14.7 (-29%) 3.2 – 26.2 0.0087
PPD ≥ 6 mm 20§ 11§ 11|| (-55%) 4 – 20¶ 0.0010**
PIBI†† 107.6 (5.8) 64.3 (10.0) 43.1 (-40%) 19.5 – 66.7 0.00069
B. Tooth- adjusted inflammatory injury ‡‡
PPD ≥ 4 mm 3.1 (0.14) 2. 1 (0.30) 0.98 (-32%) 0.28 – 1.61 0.0025
4 mm ≤ PPD < 6 mm 2.0 (0.10) 1.5 (0.20) 0.48 (-25%) 0.02 – 0.93 0.0274
PPD ≥ 6 mm 0.7§ 0.4§ 0.42|| (-56%) 0.14 – 0.76¶ 0.0025**
PIBI 4.1 (0.22) 2.7 (0.44) 1.41 (-34%) 0.41 – 2.42 0.0033
* Two-tailed P-values. †Number of periodontal pockets, mean (SE), unless otherwise indicated. ‡PPD is periodontal probing pocket depth. §Median. 
||Estimate for difference of population medians calculated as described by Campbell and Gardner [22]. ¶Approximate 95% confidence interval (CI) 
for the difference in population medians calculated as described by Campbell and Gardner [22]. **P-value by Mann-Whitney U-test. ††PIBI is 
Periodontal Inflammatory Burden Index. ‡‡Number of periodontal pockets divided by number of teeth, mean (SE), unless otherwise indicated.BMC Oral Health 2008, 8:16 http://www.biomedcentral.com/1472-6831/8/16
Page 6 of 7
(page number not for citation purposes)
periodontal inflammatory injury, evident also when
adjusted for the number of teeth.
Periodontal inflammatory burden
Untreated periodontal pockets may serve as a source of
persistent medium-grade inflammation with systemic
consequences although the inflammation is milder and
more local than in, for instance, rheumatoid arthritis. It is
noteworthy that the prevalence of rheumatoid arthritis in
the general population is about 1%, whereas the preva-
lence of gingival inflammation exceeds 50% [13]. Deep
periodontal pockets liberate more inflammatory media-
tors and cytokines than shallow pockets, thus contribut-
ing more to the inflammatory burden. We used
periodontal probing pocket depth (PPD) values to
describe periodontal inflammatory injury. The number of
tooth surfaces with increased PPD values reflects the total
inflammatory burden caused by the local periodontal
inflammation. The use of PPD instead of loss of clinical
tooth attachment (PPD + gingival recession) is well rea-
soned in this context because measurements of clinical
attachment loss do not reflect the inflammatory area of
soft tissues surrounding the teeth.
The Periodontal Inflammatory Burden Index (PIBI) devel-
oped for this study takes into account the enlargement of
inflamed subgingival surface area in the deeper periodon-
tal pockets. This is achieved by weighting the number of
advanced periodontal lesions with a coefficient 2 (see
Equation 3). The actual value of the coefficient is probably
greater than our estimate and remains to be elucidated in
future studies.
Periodontitis and CVD
Previous reports suggest that periodontal inflammation
has systemic effects and can be a burden on remote tissues
[19,32,33]. Chronic periodontitis causes deterioration of
the diabetic condition [34], oral infections increase
obstetric complications [35], and severe periodontitis is
associated with systemic inflammation and a dysmeta-
bolic status [19]. Reduced number of teeth has been
shown to be a corollary of development of CVD [36,37]
and an independent risk factor of aortic valve sclerosis
[38]. The inflammatory component could be an impor-
tant link between periodontal diseases and development
of CVD [15-18,32,39,40]. Interestingly, although atorvas-
tatin is a more potent cholesterol lowering compound
than simvastatin [41], in our study both simvastatin and
atorvastatin showed an equal association with low values
of periodontal inflammatory burden index PIBI.
Conclusion
Our results indicate that patients on statin medication
exhibit fewer clinical signs of periodontal inflammatory
injury than subjects without the statin regimen. This may
lead to development of novel therapeutic approaches, if
confirmed by consecutive prospective studies. In addi-
tion, further studies are needed to estimate the character-
istics, value and applicability of PIBI in various clinical
settings.
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